$SESN youtube.com/watch?v=xk9ZGg0... - Merck does not want to manufacture more BCG or to increase prices on BCG because it will make more money by selling expensive, more profitable drugs like Keytruda - But Keytruda being systematic will always lose to Vicinium, so I think Merck will watch Vicinium closely as it needs a compensation for low profits it makes selling BCG - This report is a clear message to the FDA that they should step in
  • 9
  • 2